MUC15 inhibits dimerization of EGFR and PI3K-AKT signaling and is associated with aggressive hepatocellular carcinomas in patients

Gastroenterology

Volumn 145, Issue 6, 2013, Pages

  Wang, Ruo Yu ^a,b   Chen, Lei ^a   Chen, Hai Yang ^a   Hu, Liang ^a,c   Li, Liang ^a   Sun, Han Yong ^b   Jiang, Feng ^a,d   Zhao, Jing ^e   Liu, Gao Mi Yang ^a   Tang, Jing ^a   Chen, Cai Yang ^a   Yang, Ying Cheng ^a   Chang, Yan Xin ^a   Liu, Hui ^b   Zhang, Jin ^b   Yang, Yuan ^b   Huang, Gang ^b   Shen, Feng ^b   Wu, Meng Chao ^b   Zhou, Wei Ping ^b,f   Wang, Hong Yang ^a,f,g   more..

^a SEMICONDUCTOR MANUFACTURING INTERNATIONAL CORPORATION   (China)

^b Eastern Hepatobiliary Surgery Hospital   (China)

^c Institute of Anal Colorectal Surgery   (China)

^d JIANGSU CANCER HOSPITAL   (China)

^e SECOND MILITARY MEDICAL UNIVERSITY   (China)

^f National Scientific Centre for Liver Cancer   (China)

^g SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Liver Cancer; Mechanism; Mouse Model; Prognostic Factor

Indexed keywords

ALPHA FETOPROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; MATRILYSIN; MESSENGER RNA; MUCIN; MUCIN 15; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; CPG ISLAND; DIMERIZATION; DOWN REGULATION; ENCAPSULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTERNALIZATION; LIVER; LIVER CELL CARCINOMA; LIVER RESECTION; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; MOUSE; NONHUMAN; OVERALL SURVIVAL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN METHYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR DIFFERENTIATION; TUMOR INVASION; UBIQUITINATION;

EID: 84888268472     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2013.08.009     Document Type: Article

References (41)

1. A. Jemal, F. Bray, and M.M. Center Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. A.P. Venook, C. Papandreou, and J. Furuse The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective Oncologist 15 2010 5 13
3. W. Alazawi, M. Cunningham, and J. Dearden Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection Aliment Pharmacol Ther 32 2010 344 355
4. J. Ferlay, H.R. Shin, and F. Bray Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 2010 2893 2917
5. J. Bruix, and M. Sherman Management of hepatocellular carcinoma: an update Hepatology 53 2011 1020 1022
6. N. Portolani, A. Coniglio, and S. Ghidoni Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications Ann Surg 243 2006 229 235
7. L.T. Pallesen, L. Berglund, and L.K. Rasmussen Isolation and characterization of MUC15, a novel cell membrane-associated mucin Eur. J. Biochem 269 2002 2755 2763
8. J. Huang, M.I. Che, and Y.T. Huang Overexpression of MUC15 activates extracellular signal-regulated kinase 1/2 and promotes the oncogenic potential of human colon cancer cells Carcinogenesis 30 2009 1452 1458
9. M.K. Shyu, M.C. Lin, and J.C. Shih Mucin 15 is expressed in human placenta and suppresses invasion of trophoblast-like cells in vitro Hum Reprod 22 2007 2723 2732
10. K. Wang, J. Liu, and Z.L. Yan Overexpression of aspartyl- (asparaginyl)-β-hydroxylase in hepatocellular carcinoma is associated with worse surgical outcome Hepatology 52 2010 164 173
11. D.X. Lin, Q.Y. Zhang, and X. Li An aggressive approach leads to improved survival in hepatocellular carcinoma patients with portal vein tumor thrombus J Cancer Res Clin Oncol 137 2011 139 149
12. H.C. Sun, W. Zhang, and L.X. Qin Positive serum hepatitis Be antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma J Hepatol 47 2007 684 690
13. A. Sorokin, M.A. Lemmon, and A. Ullrich Stabilization of an active dimeric form of the epidermal growth factor receptor by introduction of an inter-receptor disulfide bond J Biol Chem 269 1994 9752 9759
14. N. Yamada, Y. Nishida, and H. Tsutsumida Promoter CpG methylation in cancer cells contributes to the regulation of MUC4 Br J Cancer 100 2009 344 351
15. D.W. Kufe Mucins in cancer: function, prognosis and therapy Nat Rev Cancer 9 2009 874 885
16. P. Mukhopadhyay, S. Chakraborty, and M.P. Ponnusamy Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy Biochim Biophys Acta 1815 2011 224 240
17. S. Bafna, S. Kaur, and S.K. Batra Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells Oncogene 29 2010 2893 2904
18. X. Wei, H. Xu, and D. Kufe Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response Cancer Cell 7 2005 167 178
19. N. Skrypek, B. Duchene, and M. Hebbar The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the concentrative nucleoside transporter family Oncogene 32 2012 1714 1723
20. J.A. Schroeder, M.C. Thompson, and M.M. Gardner Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen activated protein kinase activation in the mouse mammary gland J Biol Chem 276 2001 13057 13064
21. Y. Li, W.H. Yu, and J. Ren Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein Mol Cancer Res 1 2003 765 775
22. K.L. Carraway 3rd, M. Funes, and H.C. Workman Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathways Curr Top Dev Biol 78 2007 1 22
23. T. Higuchi, T. Orita, and K. Katsuya MUC20 suppresses the hepatocyte growth factor-induced Grb2-Ras pathway by binding to a multifunctional docking site of met Mol Cell Biol 24 2004 7456 7468
24. R.S. Herbst, and C.J. Langer Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancer Semin Oncol 29 2002 27 36
25. S. Fujino, T. Enokibori, and N. Tezuka A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer Eur J Cancer 32 1996 2070 2074
26. S.B. Kondapaka, R. Fridman, and K.B. Reddy Epidermal growth factor and amphiregulin up-regulate matrix metallo proteinase-9 (MMP-9) in human breast cancer cells Int J Cancer 70 1997 722 726
27. S.P. Ethier Signal transduction pathways: the molecular basis for targeted therapies Semin Radiat Oncol 12 2002 3 10
28. J. Baselga, and C.L. Arteaga Critical update and emerging trends in epidermal growth factor receptor targeting in cancer J Clin Oncol 23 2005 2445 2459
29. J. Marshall Clinical implications of the mechanism of epidermal growth factor receptor inhibitors Cancer 107 2006 1207 1218
30. G. Giaccone Targeting HER/EGFR in cancer therapy: experience with erlotinib Future Oncol 1 2005 449 460
31. E. Schiffer, C. Housset, and W. Cacheux Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis Hepatology 41 2005 307 314
32. C. Berasain, J. Castillo, and J. Prieto New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system Liver Int 27 2007 174 185
33. M. Hopfner, A.P. Sutter, and A. Huether Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma J Hepatol 41 2004 1008 1016
34. A. Huether, M. Hopfner, and A.P. Sutter Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics J Hepatol 43 2005 661 669
35. S. Ueda, Y. Basaki, and M. Yoshie PTEN/AKT signalling through epidermal growth factor receptor is prerequisite for angiogenesis by hepatocellular carcinoma cells that is susceptible to inhibition by gefitinib Cancer Res 66 2006 5346 5353
36. M.C. Su, H.C. Lien, and Y.M. Jeng Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma Cancer Lett 224 2005 117 121
37. X.D. Zhu, J.B. Zhang, and P.Y. Zhuang High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma J Clin Oncol 26 2008 2707 2716
38. W. Wen, J. Ding, and W. Sun Cyclin G1-mediated epithelial-mesenchymal transition via phosphoinositide 3-kinase/Akt signaling facilitates liver cancer progression Hepatology 55 2012 1787 1798
39. H.B. El-Serag, and K.L. Rudolph Hepatocellular carcinoma: epidemiology and molecular carcinogenesis Gastroenterology 132 2007 2557 2576
40. J. Bruix, M. Sherman, and J.M. Llovet Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver J Hepatol 35 2001 421 430
41. L. Hu, L. Chen, and L. Li Hepatitis B Virus X protein enhances cisplatin-induced hepatotoxicity via a mechanism involving degradation of Mcl-1 J Virol 85 2011 3214 3228